CytoDyn Announces Settlement with Amarex Clinical Research LLC
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet
Related news for (CYDY)
- CytoDyn Releases ESMO Breast Cancer Meeting Poster
- CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
- CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
- CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
- CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab